Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
|
| Posted
:
Mon, 09 Nov 2009 10:27:38 GMT |
| Author
:
Bend Research Inc. |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company
with more than 30 years of experience in applying innovative pharmaceutical
technologies to help clients solve their most difficult scientific and
technical problems, announced today that it has entered into a collaboration
with Vertex Pharmaceuticals Incorporated, a global biotechnology company
headquartered in Cambridge, MA.
Through this new collaboration, Vertex will utilize Bend's formulation
development and manufacturing services for specific projects and clinical
trials, with the goals of both enhancing the delivery of Vertex compounds and
supporting the progression of certain Vertex product candidates through
clinical development.
The collaboration between Bend Research and Vertex is designed to
leverage the fundamental scientific capabilities of each company to solve
formulation and process-development challenges and to produce commercial drug
products that are optimized for therapeutic benefit.
"It's a great opportunity for both companies," Bend Research CEO Rod Ray
explained. "We are excited to be working with Vertex. We share their
commitment to delivering breakthrough therapies based on cutting-edge
science. Having two great teams working side by side is a powerful
combination - we look forward to a long and fruitful relationship."
Vertex's Executive Vice President of Global Research and Development and
Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend
Research exemplifies Vertex's commitment to the treatment of serious diseases
through cutting-edge science and innovative technologies. We believe Bend's
technologies and expertise will provide Vertex with important scientific
capabilities that will support our drug development efforts."
Bend Research is making its multidisciplinary team of scientists and
engineers available to companies for solving tough formulation and
development problems. Bend Research prides itself in offering fast,
innovative solutions.
Since late 2008, Bend Research has been rapidly expanding its line-up of
industrial partners. Customers that have benefitted from Bend Research's
proprietary technology and unique formulation expertise include some two
dozen major pharmaceutical companies, mid-size pharmas, and biotech companies
around the globe.
About Bend Research Inc.
Bend Research has more than 30 years of experience in helping clients
solve their most difficult scientific and technical problems. This success is
based on the company's ability to develop, advance and commercialize
pharmaceutical technologies. The firm develops innovative drug-delivery
solutions from a solid base of fundamental understanding. Bend Research
provides formulation and dosage-form support, assists in process development
and optimization, manufactures clinical trial quantities of drug candidates
in its cGMP facility, and advances promising drug candidates from conception
through to commercialization.
The company's flexible, client-focused business model and collaborative
approach to working with its customers enable long-term alliances with
clients focused on value creation.
Bend Research has more than 140 employees based in three state-of-the-art
facilities in Bend, Oregon, USA.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small-molecule
drugs for serious diseases. The company's strategy is to commercialize
products independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is focused on viral diseases, cystic
fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Contact:
Dana Settell
Bend Research Inc.
64550 Research Road
Bend, OR 97701
Phone: +1(541)-382-4100
Fax: +1(541)-382-2713
E-mail: settell@bendres.com
SOURCE Bend Research Inc.
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Tesco Mobile Network Customers to Get the iPhone LONDON, UNITED KINGDOM -- 11/25/09 --
Tesco Mobile through its joint venture partnership with O2 is pleased to announce that it will shortly introduce iPhone 3G and iPhone 3GS in Tesco Phone Shops and online through Tesco Direct in the UK.
Fitch SMARTView: No Additional Classes of U.S. Credit Card ABS Portfolio Placed 'Under Analysis' NEW YORK -
Following its monthly surveillance review of U.S. Credit Card
asset-backed securities (ABS) transactions, Fitch Ratings has not placed
any additional U.S. credit card ABS transactions 'Under Analysis'.
Five hundred and thirty classes of U.S. credit card ABS transac
Fitch Affirms Brownsville, Texas GOs at 'A+'; Upgrades BCIC's Sales Tax Bonds to 'A+' NEW YORK -
As part of ongoing surveillance, Fitch Ratings affirms its 'A+' rating
on the city's approximately $162 million of outstanding general
obligation (GO) and combination tax and revenue certificates of
obligation (CO) bonds. The Rating Outlook is revised to Stable from
Positiv
Grady P. Andrews, P.E., Joins Baker as New Mid-Atlantic Construction Services Manager for Virginia, West Virginia and Maryland RICHMOND, Va. -
Grady P. Andrews, P.E., has been appointed Mid-Atlantic construction
services manager serving the states of Maryland, Virginia and West
Virginia for Michael Baker Jr., Inc., an engineering unit of Michael
Baker Corporation (NYSE Amex:BKR). He will be responsible for
co
Westar Energy Declares Dividends TOPEKA, KS -- 11/25/09 --
The Westar Energy, Inc. (NYSE: WR) Board of
Directors today declared a quarterly dividend of 30 cents per share payable
Jan. 4, 2010 on the company's common stock.
The board also declared regular quarterly divide..
The Advisory Board Company to Present at 21st Annual Piper Jaffray Health Care Conference
WASHINGTON, Nov. 25 -- The Advisory Board Company (Nasdaq: ABCO) announced today that it will participate in the 21st Annual Piper Jaffray Health Care Conference in New York City. Speaking at the conference, on December 2, 2009 at 3:00 PM (EST), will be the Compa...
FXDD Announces Expansion into New Offices at 7 World Trade Center
a href= http://www.fxdd.com onclick= linkClick( this.href ); target= _blank title= FXDD FXDD/a is proud to announce the acquisition of a magnificent new office space at 7 World Trade Center./I/P
PNew York, NY (Vocus) November 25, 2009 -- a href= http://www.fxdd.com onclick= li...
|
|
|
|
|
|
|
|
|